BiotechTube
Genscript Biotech

Genscript Biotech

1548.HK
Nanjing, China· Est.
genscript.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

1548.HK · Stock Price

HKD 15.48+4.56 (+41.76%)
Market Cap: $4.2B

Historical price data

Market Cap: $4.2BFounded: 2002Employees: 6000+HQ: Nanjing, China

Overview

Founded in 2002, GenScript Biotech has evolved from a gene synthesis pioneer into a $24+ billion market cap global platform, serving over 200,000 clients worldwide. Its mission is to make biology easier and accelerate the transition from discovery to therapy. The company's strategy leverages its dominant Life Science Services segment as a powerful funnel to drive growth in its high-value Biologics CDMO and Cell Therapy businesses, creating a unique, synergistic ecosystem.

OncologyImmunology

Technology Platform

A vertically integrated suite of platforms spanning high-fidelity gene synthesis, antibody/protein engineering, biologics & cell therapy CDMO, and synthetic biology, designed to accelerate research and therapeutic development from discovery to commercialization.

Funding History

2
Total raised:$245M
IPO$240M
Series A$5M

Opportunities

Significant growth is driven by the expansion of Carvykti into earlier treatment lines for multiple myeloma, the rapid scaling of the high-margin biologics CDMO business, and the burgeoning market for mRNA and synthetic biology services.
The integrated platform creates a powerful funnel to capture clients across the entire R&D lifecycle.

Risk Factors

Key risks include geopolitical tensions affecting global operations, concentration risk related to the performance of Legend Biotech and Carvykti, intense pricing competition across all business segments, and execution risks in scaling complex cell therapy and biologics manufacturing.

Competitive Landscape

GenScript competes with large, diversified life science tools companies (Thermo Fisher, Danaher) in services, major global CDMOs (Lonza, WuXi Biologics) in manufacturing, and leading CAR-T developers (BMS, Gilead/Kite) in cell therapy. Its differentiation lies in its unique vertical integration from gene to therapy.

Company Timeline

2002Founded

Founded in Nanjing, China

2006Series A

Series A: $5.0M

2015IPO

IPO — $240.0M

More companies in China →